Day One Biopharmaceuticals, Inc. (DAWN)
After hours:
| Previous Close | 13.34 |
| Open | 13.31 |
| Bid | 13.67 x 100 |
| Ask | 13.76 x 100 |
| Day's Range | 13.28 - 13.91 |
| 52 Week Range | 11.30 - 18.07 |
| Volume | |
| Avg. Volume | 1,065,545 |
| Market Cap | 1.384B |
| Beta (5Y Monthly) | -1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.97 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.00 |
GlobeNewswireDay One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman’s departure planned for end of 2024 Company’s search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be
- GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST. A live webcast of the discussion will be available by visiti
